Business context and reporting period
Important entity mismatch: The request identifies Citius Oncology, Inc., but the supplied filing is TenX Keane Acquisition’s Form 10-Q for the quarter ended June 30, 2023. This summary reflects the supplied TenX filing, not Citius Oncology.
TenX is a Cayman Islands SPAC formed to pursue a business combination. It had not begun operating or generating revenue as of June 30, 2023. The filing identifies the company as a shell company.
Financial results and position
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 |
|---|---|---|
| Operating revenue | None | None |
| General and administrative costs | $199,554 | $347,476 |
| Trust investment interest income | $815,850 | $1,575,497 |
| Net income | $616,296 | $1,228,021 |
| Net income per share | $0.07 | $0.14 |
- At June 30, 2023, total assets were $69.85 million, including $69.39 million in the trust account and $370,095 of cash outside the trust.
- Current liabilities were $463,875, including $349,975 due to the sponsor and $108,899 of accrued expenses. Shareholders’ equity was a deficit of $1,968. The filing reports no long-term debt obligations.
- For the first six months, operating activities used $269,055; financing activities provided $349,975, consisting of sponsor advances. Cash increased by $80,920.
- Trust investments and redeemable shares increased from $67.81 million at December 31, 2022 to $69.39 million at June 30, 2023. Redeemable shares were recorded outside permanent equity.
Changes versus the prior comparable period
The company reported no revenue and no net income or loss for the three- or six-month periods ended June 30, 2022. In 2023, trust interest drove positive net income, partly offset by operating expenses. Six-month operating costs were $347,476. The filing attributes the improvement in results primarily to interest earned on trust assets; this is not operating performance from a business.
Outlook, risks and unusual items
- Business-combination deadline and going concern: Management disclosed substantial doubt about the company’s ability to continue as a going concern because it may not complete a business combination within the permitted period. The filing states there is no assurance a transaction will be completed, and the financial statements contain no adjustments for the uncertainty.
- Subsequent extension: On July 18, 2023, the company deposited $660,000 into the trust to extend its deadline by three months, to October 18, 2023. The sponsor funded this through a non-interest-bearing note repayable upon a business combination; the sponsor may elect to convert eligible amounts into private units, subject to the stated terms.
- Liquidity: The $370,095 of outside-trust cash is intended to fund target searches, diligence and public-company costs. The company may need sponsor financing or other financing to complete a transaction; sponsor loans are not assured. Trust funds are generally reserved for a business combination or shareholder redemptions.
- Redemptions and liquidation: Public shareholders may redeem shares in connection with a business combination. If no transaction is completed by the applicable deadline, the company must cease operations and redeem public shares, subject to applicable requirements. Per-share proceeds could be below the original $10 offering price.
- Related parties: Sponsor advances of $349,975 were due on demand at quarter-end. The company also pays the sponsor $10,000 per month for administrative services and reported $60,000 of expense for the first half of 2023.
- Management said disclosure controls were effective as of June 30, 2023, with no material change in internal control over financial reporting. The company reported no material litigation and no market or interest-rate risk as of quarter-end.
Investor verification points
- Verify the issuer and filing: the supplied document is for TenX Keane Acquisition, not Citius Oncology, Inc.
- Check the status and terms of the October 18, 2023 business-combination deadline extension, including the $660,000 sponsor note and any later extensions or transaction developments.
- Review current outside-trust cash, sponsor advances, expenses and available financing against the company’s limited pre-combination runway.
- Assess trust-account value, redemption levels, and the potential effect of redemptions or additional financing on transaction feasibility and remaining shareholders.
- Distinguish trust interest income and redemption-value adjustments from operating revenue and the economics of any eventual combined company.